Blog

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova/LinkedIn

Jan 28, 2025, 08:26

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, posted the following on LinkedIn:

“Daraxonrasib (RMC-6236), an investigational pan-RAS inhibitor, shows promising early results in RAS-mutant PDAC, with a 36% response rate in second-line therapy and a median overall survival of 14.5 months. Common toxicities include rash, diarrhea, and nausea, but they are mostly manageable. The phase 3 RASolute trial is ongoing to compare it with standard chemotherapy.

I’m thrilled to have had the opportunity to join the phase 1 trial of this groundbreaking drug at IEO Istituto Europeo di Oncologia.”

cancer chemotherapy alternatives clinical trials DaraxONRASib Elvina Almuradova IEO Istituto Europeo di Oncologia OncoDaily Oncology oncology research Pancreatic Cancer RAS mutation RMC-6236 targeted therapy

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer